Financial Data and Key Metrics Changes - Novartis achieved high single-digit growth with an 8% increase in sales and a 14% rise in core operating income for the full year 2025, reaching a core margin of 40.1% [4][35] - For Q4, sales declined by 1%, while core operating income increased by 1%, with core EPS rising 2% to $2.03 [5][38] - Free cash flow reached an all-time high of CHF 17.6 billion, growing 8% year-over-year [35][39] Business Line Data and Key Metrics Changes - Kisqali sales grew 57% year-over-year to CHF 4.8 billion, with Q4 growth at 44% [6][7] - Kesimpta saw a 36% increase to $4.4 billion, with a 27% growth in Q4 [10] - Pluvicto achieved $2 billion in global sales, with a 75% increase in the U.S. [12] - Leqvio reached blockbuster status with 57% growth for the year [14] - Scemblix also reached blockbuster status with 87% growth in Q4 [15] Market Data and Key Metrics Changes - Kisqali's U.S. sales growth was 62%, with over 80% NBRX share in Germany for early breast cancer [7][9] - Kesimpta is leading in NBRX share in 9 out of 10 major markets outside the U.S. [10] - Pluvicto secured approvals in Japan and China, contributing to strong growth outside the U.S. [12] - Scemblix has a 41% NBRX share in the U.S. and 72% in the third-line setting across major markets [17] Company Strategy and Development Direction - Novartis aims to grow through the largest patent expiry in its history, focusing on key growth brands and pipeline replacement [6] - The company plans to continue investing in R&D while managing productivity improvements [43][44] - Novartis is committed to maintaining a 5%-6% sales CAGR from 2025 to 2030 [44][49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving mid-single-digit sales growth in 2026 despite anticipated challenges from generic entries [43][44] - The company expects to return to a core margin of over 40% by 2029 [44] - Management highlighted the importance of pipeline advancements and upcoming pivotal readouts in 2026 [32][50] Other Important Information - Novartis has completed its CHF 15 billion share buyback program and initiated a new CHF 10 billion program [41] - The proposed dividend for 2025 is CHF 3.70 per share, marking a 6% increase [41][42] Q&A Session Questions and Answers Question: Insights on remibrutinib and FDA conversations - Management noted that remibrutinib has an approved label without liver safety discussions, and they plan to advocate for limited liver monitoring based on FDA feedback [53][54] Question: Commercial opportunities for remibrutinib in MS - Management indicated that the commercial opportunity will depend on data-driven results, with a significant market for oral options in MS [60][61] Question: Thoughts on Pelacarsen's event-based study risks - Management expressed confidence in the study's design and powering assumptions, despite lower than expected event rates [62][63] Question: Launch plans for Rhapsido and Ianalumab in an MFN world - Management acknowledged the importance of adjusting launch strategies for significant assets like Rhapsido and Ianalumab in the ex-U.S. market [73]

Banco Santander (Brasil) (NYSE:BSBR) Q4 2025 Earnings call February 04, 2026 08:00 AM ET Speaker3Good morning, everyone. Thank you for joining us for our fourth quarter 2025 earnings video conference call. We are live from our headquarters in São Paulo, and we will divide this event into three parts. First, Mário Leão will address the main highlights of the quarter and the directions for our growth in the coming periods. Next, Gustavo Alejo will provide a detailed analysis of our performance, and finally, w ...

Cabot (NYSE:CBT) Q1 2026 Earnings call February 04, 2026 08:00 AM ET Speaker6Ladies and gentlemen, thank you for standing by, and welcome to the first quarter fiscal year 2026 Cabot Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is raised, and ...

Aurora Cannabis (NasdaqCM:ACB) Q3 2026 Earnings call February 04, 2026 08:00 AM ET Speaker3Welcome to the Aurora Cannabis Inc. third quarter 2026 results conference call. All participants will be in a listen-only mode, and a question-and-answer session will follow the formal presentation. This conference call is being recorded today, Wednesday, February 4, 2026. I would now like to turn the conference over to your host, Kevin Nyland, Director of Strategic Finance and Investor Relations. Please go ahead, sir ...

Financial Data and Key Metrics Changes - The company closed 2025 with $1.78 trillion in assets under management, up over 10% from the start of the year, despite $56.9 billion in net outflows [4] - Adjusted diluted earnings per share for Q4 2025 was $2.44, bringing full-year adjusted diluted EPS to $9.72, which is up 4.2% from 2024 [16] - Q4 adjusted net revenue was $1.9 billion, raising full-year adjusted net revenue to nearly $7.4 billion, an increase of 2.8% from 2024 [18] - Adjusted operating expenses for Q4 were $1.2 billion, bringing full-year adjusted operating expenses to $4.6 billion, which is up 3.4% from 2024 [21] Business Line Data and Key Metrics Changes - Net outflows were concentrated in the equity and mutual fund business, with $75 billion of net outflows from equity and almost $64 billion from mutual funds in 2025 [5] - Fixed income and alternatives had positive net flows for the quarter, with fixed income delivering eight consecutive quarters of positive net flows [17] - The target date franchise ended the year with net inflows of $5.2 billion, while the ETF business had $1.8 billion in net inflows during the quarter [17] Market Data and Key Metrics Changes - The company experienced elevated redemptions from its legacy equity and mutual fund business, but strong equity market returns offset the net outflows [16] - The average effective fee rate for Q4 was 38.8 basis points, down from 39.1 basis points in Q3 2025, driven by changes in asset and vehicle mix [19] Company Strategy and Development Direction - The company established a strategic collaboration with Goldman Sachs to pursue opportunities in wealth and retirement through co-developed public-private offerings [9] - The company is focused on integrating digital capabilities and enhancing its strategic vision through organizational changes [13] - The company plans to launch an active crypto ETF in 2026, utilizing a blend of fundamental and quantitative analysis [34] Management's Comments on Operating Environment and Future Outlook - Management noted that the biggest factor affecting operating margins is equity market returns, with a portion of the expense base being variable [26] - The company anticipates continued pressure in equities but expects to offset this with inflows in target-date funds and growth in fixed income and alternatives [45] - Management expressed confidence in the company's strategic initiatives and the ability to navigate changing market cycles [22] Other Important Information - The company returned nearly $1.8 billion of cash to stockholders and extended its regular dividend for the 39th consecutive year [5] - The company launched 13 ETFs in 2025, bringing the total to 30, with assets under management growing to over $21 billion at year-end [11] Q&A Session Summary Question: How is the company planning for 2026 in terms of operating expenses? - Management indicated that a third of the expense base is variable and that they are balancing cost savings with investments in growth areas [26][28] Question: What is the company's approach to tokenization and blockchain? - The company is exploring efficiency opportunities, product opportunities, and distribution opportunities related to tokenization and blockchain [33] Question: What is the outlook for the target date business given recent outflows? - Management noted that outflows were driven by M&A activity and that the company is well-positioned to mitigate headwinds with strong blend and hybrid offerings [43][44] Question: How does the company expect to respond to recent market disruptions? - Management stated that client reactions vary, but the overall impact on flows is not expected to be substantial in the long term [48] Question: What is the company's exposure to investments potentially disrupted by AI? - Management emphasized that they have a rigorous credit process and are well-positioned to navigate potential disruptions in the market [53]

Champion Homes (NYSE:SKY) Q3 2026 Earnings call February 04, 2026 08:00 AM ET Speaker7Good morning, and welcome to the Champion Homes third quarter fiscal 2026 earnings call. Here to review the results are Tim Larson, Champion Homes President and Chief Executive Officer, Dave McKinstry, Champion Homes Executive Vice President, Chief Financial Officer, and Treasurer, and Laurie Hough, Champion's former Executive Vice President, Chief Financial Officer, and Treasurer, who announced her retirement in December. ...

LATAM Airlines Group (NYSE:LTM) Q4 2025 Earnings call February 04, 2026 08:00 AM ET Speaker1Hello and welcome everyone to the 4Q 2025 LATAM Airlines Group Earnings Conference Call. My name is Becky, and I will be your operator today. Before I turn the call over to management, I'd like to remind you that certain statements in this presentation and during the Q&A may relate to future events and expectations, and as such constitute forward-looking statements. Any matters discussed today that are not historical ...

Uber Technologies (NYSE:UBER) Q4 2025 Earnings call February 04, 2026 08:00 AM ET Speaker4I'd like to welcome everyone to today's Uber Q4 and full year 2025 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you'd like to ask a question during this time, simply press star followed by the number one on your telephone keypad. And if you'd like to withdraw your question, simply press star one ...

Reynolds Consumer Products (NasdaqGS:REYN) Q4 2025 Earnings call February 04, 2026 08:00 AM ET Speaker6A reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jill Koval, Director of Investor Relations. Thank you, Jill. You may begin.Speaker2Thank you, operator, and good morning, everyone. Thank you for joining us for Reynolds Consumer Products' fourth quarter earnings conference call. Today's call is being webcast, and a replay will be available on the investor relation ...

Financial Data and Key Metrics Changes - Fourth quarter consolidated revenue reached $5.286 billion, representing a 15.9% reported growth compared to Q4 2024, with operational revenue growth of 14.3% after excluding a $74 million foreign exchange tailwind [18] - Full year 2025 consolidated revenue was $20.074 billion, marking a 19.9% reported growth versus 2024, with operational revenue growth of 19.2% after excluding a $114 million foreign exchange tailwind [19] - Adjusted EPS for Q4 2025 was $0.80, a 15% increase from 2024, exceeding guidance [18] - Full year 2025 adjusted EPS was $3.06, growing 22% versus 2024, also exceeding guidance [19] - Adjusted gross margin for Q4 was 70.7%, with a full year adjusted gross margin of 70.6%, reflecting a 30 basis point expansion [20] Business Line Data and Key Metrics Changes - Urology sales grew 13% operationally in Q4 and 23% operationally for the full year, but performance was below expectations [4] - Endoscopy achieved organic growth of 8% in both Q4 and for the full year, driven by endoluminal surgery and imaging systems [4] - Neuromodulation grew 10% in Q4 and delivered 8% organic growth for the full year, with strong performance from the brain franchise [5] - Cardiovascular segment delivered 16% growth operationally in Q4 and 22% operationally for the full year [6] - Watchman business grew 29% in Q4 and maintained strong double-digit growth for the full year [12] Market Data and Key Metrics Changes - U.S. operational growth was 17% in Q4 and 26% for the full year, with strong performance in EP, Watchman, and ICTX [2] - Asia Pacific region grew 15% operationally in Q4 and 14% for the full year, led by Japan and China [3] - Europe, Middle East, and Africa grew 5% in Q4 and 3% for the full year, with high single-digit growth excluding Acclarent discontinuation [2] Company Strategy and Development Direction - The company anticipates continued momentum in EP and Watchman, with expectations for higher growth in the second half of 2026 [3] - Strategic acquisitions, including Penumbra and Valencia Technologies, are aimed at entering high-growth markets and expanding product offerings [24][6] - The company is focused on maintaining a strong pipeline of innovative products and expanding its market share in key segments [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 10%-11% organic revenue growth for 2026, with adjusted EPS growth of 12%-14% [27] - The company expects to face challenges in the first half of 2026 due to product removals and market adjustments but anticipates stronger performance in the latter half [25][43] - Management highlighted the importance of ongoing investments in R&D and strategic M&A to drive long-term growth [61] Other Important Information - The company reported free cash flow of $3,659 million for the full year 2025, exceeding expectations [22] - The legal reserve was $242 million as of December 31, with $46 million already funded [24] - The company maintains a strong balance sheet with cash on hand of $1.965 billion and a gross debt leverage ratio of 1.9 times [23] Q&A Session Summary Question: Concerns about U.S. EP and Watchman performance - Management reassured that Q4 results exceeded internal targets, with EP growing 35% and Watchman growing 29%, indicating strong market share gains [30][34] Question: Impact of recent trials on Watchman - Management confirmed no negative impact from recent trials and emphasized robust uptake of Watchman procedures [36][38] Question: Expectations for EP growth in 2026 - Management expects EP growth to exceed 15%, driven by new product approvals and market expansion [41][42] Question: Diversification of growth drivers - Management highlighted strong performance expected in Neuromod, Urology, and Endoscopy, with ongoing investments to ensure consistent growth across all business units [59][60]